Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ARTELO BIOSCIENCES, INC. (ARTL)

Artelo Biosciences to effect 1-for-9 reverse stock split effective August 28, 2026

Neutral Impact 3 of 5 shareholder Written later

Artelo Biosciences filed a Certificate of Change in Nevada on August 26, 2026, to carry out a 1-for-9 reverse stock split of its common stock. The split takes effect at 5:00 p.m. Eastern Time on August 28, 2026, and the company said it is intended to improve the stock's marketability and liquidity. Each holder's pro-rata ownership is stated to remain unchanged, though the share count falls and the new CUSIP changes.

Key points

  • Each nine pre-split shares combine into one new share; outstanding shares fall from 4,929,966 to approximately 547,774.
  • Authorized common shares are reduced from 500,000,000 to 55,555,556.
  • Shares are expected to begin trading on a split-adjusted basis on Nasdaq on August 31, 2026, under new CUSIP 04301G805.
  • No fractional shares will be issued; holders entitled to a fraction receive one whole share.

The filing

CompanyARTELO BIOSCIENCES, INC. (ARTL)
Form8-K, current report
Filed with the SECAug 27, 2026, 8:30 AM ET
Accession number0001640334-26-001421

Items reported: 3.03 Change to Shareholder Rights5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.